Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset
Type 1 Diabetes TrialNet Canakinumab Study Group (Lise Tarnow, members) , The AIDA Study Group (Flemming Pociot, members), Flemming Pociot (Member of study group), Jørgen Rungby (Member of study group)
Dive into the research topics of 'Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset'. Together they form a unique fingerprint.